US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction. The combined company expects pro-forma cash of around $700m at closing. Candid chairman, president and CEO Dr Ken Song will lead the new entity. Rallybio co-founder and CEO Dr Stephen Uden said: "We are pleased to announce this transaction, which we believe represents a compelling opportunity for Rallybio stockholders to participate in the future value creation of a well-ca ...